- Home
- TMQ vs ZLAB Comparison
TMQ vs ZLAB Comparison
Compare TMQ & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | ZLAB |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TMQ | ZLAB |
|---|---|---|
| Price | $4.70 | $17.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $57.22 |
| AVG Volume (30 Days) | ★ 5.2M | 806.0K |
| Earning Date | 09-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $1.06 | $17.75 |
| 52 Week High | $11.29 | $44.34 |
Technical Indicators
Market Signals| Indicator | TMQ | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 18.27 |
| Support Level | $4.30 | $19.40 |
| Resistance Level | $4.99 | $20.22 |
| Average True Range (ATR) | 0.33 | 0.52 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 74.57 | 1.83 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.